New schizophrenia drug tested in teens – safe but no cure

NCT ID NCT02411695

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated May 11, 2026 · Updated 1 time

Summary

This early-stage study tested the safety of the medication brexpiprazole in 43 teenagers aged 13 to 17 with schizophrenia. Researchers monitored side effects, vital signs, and how the drug moved through the body over 17 days. The goal was to see if the drug is safe enough for larger studies, not to cure the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Study site

Little Rock, Arkansas, 72211, United States
Study site

Culver City, California, 90230, United States
Study site

Orange, California, 92858, United States
Study site

Washington D.C., District of Columbia, 20016, United States
Study site

Atlanta, Georgia, 30331, United States
Study site

Marlton, New Jersey, 08053, United States
Study site

Cincinnati, Ohio, 45219, United States
Study site

Cleveland, Ohio, 44106, United States
Study site

The Woodlands, Texas, 77381, United States
Study site

Orem, Utah, 84058, United States

Conditions

Explore the condition pages connected to this study.

SCHIZOPHRENIA